Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too

Executive Summary

Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.

Advertisement

Related Content

EU Orphan Designations Fall Sharply In 2017
Novartis' Kisqali Impresses In Premenopausal Breast Cancer As Market Crowds
EU Moves To RATIFY Novartis' Rydapt for AML
Sarilumab Set To Clear EU Hurdle In RA But Actemra Specter Remains
Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100146

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel